BIOMAT Database Logo BIOMAT Database Logo

[A randomized controlled study to compare 1-hexylcarbamoyl-5-fluorouracil (HCFU) and 1-(2-tetrahydrofuryl)-5-fluorouracil (Tegafur) for the prevention of post-operative recurrence of bladder cancer]. 1985

T Misaki, and H Hisazumi, and A Sakai, and T Nakamura, and S Kanda, and I Mikawa, and T Miyagi, and T Katsumi, and M Orito, and K Kawaguchi

To evaluate the effect of 1-hexylcarbamoyl-5-fluorouracil (HCFU), a derivative of 5-fluorouracil (5-FU), in preventing postoperative recurrence of bladder cancer, a randomized controlled study with 1-(2-tetrahydrofuryl)-5-fluorouracil (Tegafur) as the reference standard was performed. HCFU was given orally 600 mg a day and Tegafur was given orally, 800 mg a day. The following results were obtained: Of 103 patients, 51 were given HCFU and 52 Tegafur, the non-recurrence rate in the group treated with HCFU was 70.8% after 1 year and 54.9% after 2 years of follow up, and that of the group treated with Tegafur was 56.5% and 46.2% respectively. The rate of non-recurrence in the HCFU group was significantly higher (p less than 0.01) than that of the Tegafur group during the period of follow up between 450 and 539 days. Of the 87 patients, who took the drugs for more than 90 days, the rate of non-recurrence in 43 patients receiving HCFU was 79.2% after 1 year and 60.4% after 2 years, compared to 62.5% and 50.0% respectively for 44 patients receiving Tegafur. The non-recurrence rate of the HCFU group was also significantly higher than that of the Tegafur group in the period between 450 and 539 days after operation (p less than 0.05). The incidence of side effects was 35.6% and 51.7% in HCFU and Tegafur patients, respectively. No significant difference of side effects was found between HCFU and Tegafur.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D011184 Postoperative Period The period following a surgical operation. Period, Postoperative,Periods, Postoperative,Postoperative Periods
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D001743 Urinary Bladder A musculomembranous sac along the URINARY TRACT. URINE flows from the KIDNEYS into the bladder via the ureters (URETER), and is held there until URINATION. Bladder,Bladder Detrusor Muscle,Detrusor Urinae,Bladder Detrusor Muscles,Bladder, Urinary,Detrusor Muscle, Bladder,Detrusor Muscles, Bladder
D001749 Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER. Bladder Cancer,Bladder Neoplasms,Cancer of Bladder,Bladder Tumors,Cancer of the Bladder,Malignant Tumor of Urinary Bladder,Neoplasms, Bladder,Urinary Bladder Cancer,Bladder Cancers,Bladder Neoplasm,Bladder Tumor,Cancer, Bladder,Cancer, Urinary Bladder,Neoplasm, Bladder,Neoplasm, Urinary Bladder,Tumor, Bladder,Tumors, Bladder,Urinary Bladder Neoplasm
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females

Related Publications

T Misaki, and H Hisazumi, and A Sakai, and T Nakamura, and S Kanda, and I Mikawa, and T Miyagi, and T Katsumi, and M Orito, and K Kawaguchi
Sensitivity test for 5-fluorouracil and its analogues, 1-(2-tetrahydrofuryl)-5-fluorouracil, uracil/1-(2-tetrahydrofuryl)-5-fluorouracil (4:1) and 1-hexylcarbamoyl-5-fluorouracil, using the subrenal capsule assay.
January 1988, Oncology,
T Misaki, and H Hisazumi, and A Sakai, and T Nakamura, and S Kanda, and I Mikawa, and T Miyagi, and T Katsumi, and M Orito, and K Kawaguchi
1-Hexylcarbamoyl-5-fluorouracil (HCFU)--a masked 5-fluorinated pyrimidine.
June 1981, Cancer treatment reviews,
T Misaki, and H Hisazumi, and A Sakai, and T Nakamura, and S Kanda, and I Mikawa, and T Miyagi, and T Katsumi, and M Orito, and K Kawaguchi
Randomized controlled trial of 5-fluorouracil (5-FU) infusion combined with 1-hexylcarbamoyl-5-fluorouracil (HCFU) oral administration and HCFU alone as postoperative adjuvant chemotherapy for colorectal cancer.
January 2000, Anticancer research,
T Misaki, and H Hisazumi, and A Sakai, and T Nakamura, and S Kanda, and I Mikawa, and T Miyagi, and T Katsumi, and M Orito, and K Kawaguchi
Post-operative adjuvant chemotherapy for colorectal cancer with 5-fluorouracil (5-FU) infusion combined with 1-hexylcarbamoyl-5-fluorouracil (HCFU) oral administration after curative resection.
January 2001, Anticancer research,
T Misaki, and H Hisazumi, and A Sakai, and T Nakamura, and S Kanda, and I Mikawa, and T Miyagi, and T Katsumi, and M Orito, and K Kawaguchi
UFT is more antineoplastic against gastric carcinoma than 5-fluorouracil, 1-(2-tetrahydrofuryl)-5-fluorouracil and 1-hexylcarbamoyl-5-fluorouracil.
January 1988, Chemotherapy,
T Misaki, and H Hisazumi, and A Sakai, and T Nakamura, and S Kanda, and I Mikawa, and T Miyagi, and T Katsumi, and M Orito, and K Kawaguchi
Review of a new antimetabolic agent 1-hexylcarbamoyl-5-fluorouracil (HCFU).
January 1980, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,
T Misaki, and H Hisazumi, and A Sakai, and T Nakamura, and S Kanda, and I Mikawa, and T Miyagi, and T Katsumi, and M Orito, and K Kawaguchi
[Blood level of 5-fluorouracil (5-FU) by oral administration of 1-hexylcarbamoyl-5-fluorouracil (HCFU) and tegafur in patients with hepatocellular carcinoma].
October 1985, Nihon Gan Chiryo Gakkai shi,
T Misaki, and H Hisazumi, and A Sakai, and T Nakamura, and S Kanda, and I Mikawa, and T Miyagi, and T Katsumi, and M Orito, and K Kawaguchi
[Clinical evaluation of 1-hexylcarbamoyl-5-fluorouracil (HCFU) in hepatocellular carcinoma].
November 1984, Gan to kagaku ryoho. Cancer & chemotherapy,
T Misaki, and H Hisazumi, and A Sakai, and T Nakamura, and S Kanda, and I Mikawa, and T Miyagi, and T Katsumi, and M Orito, and K Kawaguchi
Phase I study of a new antitumor drug, 1-hexylcarbamoyl-5-fluorouracil (HCFU), administered orally: an HCFU clinical study group report.
January 1980, Cancer treatment reports,
T Misaki, and H Hisazumi, and A Sakai, and T Nakamura, and S Kanda, and I Mikawa, and T Miyagi, and T Katsumi, and M Orito, and K Kawaguchi
[Evaluation of the therapeutic effect of HCFU (1-hexylcarbamoyl-5-fluorouracil) on non-resectable stomach cancer].
January 1982, Gan to kagaku ryoho. Cancer & chemotherapy,
Copied contents to your clipboard!